Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314737 | 0.91 | TLR7 (0.43) | TLR7TLR8ADORA3ADORA2ACDC7 | |
| SCHEMBL29321163 | 0.90 | ROCK1 (0.38) | TLR7TLR8ADORA3ADORA2AAPP | |
| SCHEMBL29314742 | 0.86 | TLR8 (0.36) | TLR7TLR8MAP4K4 | |
| SCHEMBL29314735 | 0.86 | ADORA3 (0.37) | TLR7TLR8ADORA3ADORA2AAPP | |
| SCHEMBL23037637 | 0.84 | TLR8 (0.43) | TLR7TLR8ADORA3ADORA2A | |
| SCHEMBL30539889 | 0.83 | TLR8 (0.41) | TLR7TLR8ADORA3ADORA2ATP53 | |
| SCHEMBL23037575 | 0.83 | TLR8 (0.41) | TLR7TLR8ADORA3ADORA2ATP53 | |
| SCHEMBL29314743 | 0.83 | TLR8 (0.39) | TLR7TLR8ADORA3ADORA2ALMNA | |
| SCHEMBL23037577 | 0.81 | TLR8 (0.43) | TLR7TLR8ADORA3ADORA2A | |
| SCHEMBL29321148 | 0.81 | TLR7 (0.41) | TLR7TLR8ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR7 236/4885TLR8 210/4885ADORA3 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.